Researchers targeted ZFP384 using antisense therapy in mouse models of stroke. The strategy sustained microglial repair activity and enhanced recovery, even with delayed treatment, highlighting a new ...

Stroke is one of the leading causes of long-term disability worldwide and often results in impairments in movement, speech ...

Blocking the activity of ZFP384 can prolong the brain’s endogenous repair functions after stroke, report researchers in a ...

Glial biology has evolved from viewing glia as passive support cells to understanding them as essential regulators of brain development, homeostasis, and ...

Traumatic brain injury (TBI) affects millions of people worldwide every year and remains a major cause of long-term disability, cognitive decline, and neurological complications.

The FDA has given the green light for a first-in-human trial testing PTD802, an oral remyelination therapy for multiple sclerosis. The treatment candidate from Pheno Therapeutics is designed to boost ...